紫杉醇联合顺铂治疗晚期非小细胞肺癌的临床观察

目的观察紫杉醇(PTX)加顺铂(CDDP)联合化疗治疗晚期非小细胞肺癌的近期疗效及毒副反应。方法PTX135~175mg/m2静脉滴注,第1天;CDDP75mg/m2,分三次用完。每21天为1个周期,连用2或3周期。结果可评价疗效者37例,其中PR16例,总有效率为43.2%。毒副反应主要是骨髓抑制和恶心呕吐。结论PTX DDP治疗晚期非小细胞肺癌可获得较高疗效,毒副反应轻,是一个较好的联合化疗方案。

A clinical study on paxlitaxel plus cisplatin combined therapy in the treatment of non-small cell lung cancer

Objective To evaluate the efficacy and toxicity of conbined chemotherapy with paclitaxel (PTX) plus cisplatin (DDP) in the treatment of advanced non-small cell lung cancer (NSCLC).Methods From July 2003 to July 2005 37 patients with advanced non-small cell lung cancer received PTX 135~175mg/m2 by intravenous infusion, on day 1, and CDDP 75mg/m2 by intravenous infusion, in the following 3 days. The treatment period was 3 weeks per cycle for 2 or 3 cycles.Results Thirty-seven patients were evaluable for efficacy. Sixteen patients got partial response with an overall response rate of 43.2%. The main toxicities were myelosuppression and nausea. The other side effects were mild.Conclusion A high response rate can be obtained in advanced NSCLC by PTX plus DDP. PTX is a promising antitumor agent with tolerable toxicity.